Wall Street brokerages expect OptiNose, Inc. (NASDAQ:OPTN) to report ($0.37) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for OptiNose’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.37). OptiNose posted earnings per share of ($0.43) in the same quarter last year, which suggests a positive year-over-year growth rate of 14%. The firm is expected to report its next earnings results on Thursday, November 4th.
According to Zacks, analysts expect that OptiNose will report full-year earnings of ($1.57) per share for the current financial year, with EPS estimates ranging from ($1.65) to ($1.50). For the next year, analysts expect that the firm will post earnings of ($0.84) per share, with EPS estimates ranging from ($0.95) to ($0.74). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that follow OptiNose.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings results on Wednesday, August 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.02). The business had revenue of $18.36 million for the quarter, compared to analysts’ expectations of $17.35 million. OptiNose had a negative return on equity of 1,275.55% and a negative net margin of 152.39%.
OptiNose stock traded down $0.01 during trading on Thursday, reaching $3.01. The company had a trading volume of 1,261 shares, compared to its average volume of 365,691. The firm’s 50-day simple moving average is $2.81 and its 200 day simple moving average is $3.11. OptiNose has a 1-year low of $2.32 and a 1-year high of $5.11. The firm has a market capitalization of $160.46 million, a PE ratio of -1.65 and a beta of 0.99. The company has a debt-to-equity ratio of 18.44, a quick ratio of 2.55 and a current ratio of 2.83.
In other news, COO Ramy A. Mahmoud sold 12,499 shares of the business’s stock in a transaction dated Thursday, September 16th. The stock was sold at an average price of $2.79, for a total transaction of $34,872.21. Following the completion of the transaction, the chief operating officer now directly owns 294,264 shares of the company’s stock, valued at $820,996.56. The sale was disclosed in a filing with the SEC, which is accessible through this link. 6.00% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. GMT Capital Corp raised its position in OptiNose by 748.6% in the second quarter. GMT Capital Corp now owns 1,110,702 shares of the company’s stock worth $3,454,000 after acquiring an additional 979,820 shares in the last quarter. Millennium Management LLC boosted its stake in OptiNose by 939.6% in the 2nd quarter. Millennium Management LLC now owns 689,751 shares of the company’s stock worth $2,145,000 after buying an additional 623,403 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in OptiNose in the 2nd quarter worth about $1,520,000. Morgan Stanley boosted its stake in OptiNose by 4,823.6% in the 2nd quarter. Morgan Stanley now owns 448,984 shares of the company’s stock worth $1,396,000 after buying an additional 439,865 shares during the last quarter. Finally, Opaleye Management Inc. raised its holdings in shares of OptiNose by 48.5% in the 2nd quarter. Opaleye Management Inc. now owns 1,226,600 shares of the company’s stock worth $3,815,000 after purchasing an additional 400,600 shares during the period. Institutional investors own 42.51% of the company’s stock.
OptiNose Company Profile
OptiNose, Inc operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Featured Article: How does equity income fit into an investing strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.